Sonova
misses targets as Costco, cochlear implants hurt results
Send a link to a friend
[May 18, 2016]
ZURICH (Reuters) - Sonova on
Wednesday missed full-year sales and profit targets that the Swiss
hearing aid maker had already cut last year as cochlear implant sales
remained sluggish and big U.S. retailer Costco slashed prices on its
own-brand products.
|
Sales in local currency rose 5.8 percent to 2.07 billion Swiss
francs ($2.11 billion) in the company's fiscal year to March, it
said in a statement, behind Sonova's 6-8 percent target. Constant
currency earnings before interest, taxes and amortization rose 1.4
percent to 430.6 million francs, compared to its 3-7 percent goal.
Income after taxes fell to 345 million francs, from 368 million
francs in 2014/2015.
Sonova fell short as results were dented by a U.S. cochlear implant
business that has not shifted from children to adults as quickly as
anticipated and by customer Costco's focus on its own
Kirkland-brand hearing aids at prices that Sonova's devices
struggled to compete against.
"Costco has changed the strategy with Kirkland, they lowered the end
user price by another $200 for two instruments, so they are down now
from $2,000 to $1,800 for two fully fitted instruments, and that's a
brutal low price," said Sonova Chief Executive Officer Lukas
Braunschweiler in an interview.
This month, Sonova said it was buying Netherlands' retailer
AudioNova as it seeks to revive momentum and counter threats from
rivals such as Signia, William Demant and GN Store Nord, which are
also buying retailers where they remove competing products from the
shelves.
[to top of second column] |
For the current year, Sonova expects sales to grow in the range of 4
to 6 percent and EBITA to increase by 3 to 7 percent, both measured
in local currencies.
Sonova's shares were seen falling 2.4 percent in Zurich, according
to premarket indicators.
(Reporting by John Miller, editing by Louise Heavens)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|